Objectives: To characterize the cognitive abilities of patients with primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) compared with healthy controls (HCs) matched for age, sex, and education level while considering the different characteristics of PPMS and RRMS and to compare the cognitive patterns of these types of multiple sclerosis.
Little information is available on the cognitive dysfunction that occurs in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting multiple sclerosis (RRMS). This is largely attributable to the methodologic flaws of some studies that used inappropriate control groups that did not account for differences in age, sex, and education level that are common between RRMS and PPMS patient groups. The first study comparing cognitive performance in a homogeneous sample of patients with PPMS with cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) found cognitive impairment in 7% of patients with PPMS vs 53% of patients with SPMS who had similar physical disabilities. 1 In the MAGNIMS (Magnetic Resonance Networks in Multiple Sclerosis) study, 2 63 patients with PPMS or transitional progressive multiple sclerosis (MS) were paired with controls and 28.6% of patients were diagnosed as cognitively impaired. In contrast, some studies that have compared, with similar methodologies, selected samples of patients with PPMS and RRMS, found more impairment in patients with PPMS than in patients with RRMS. 3, 4 However, these studies did not use separate control groups.
The aim of that study was to compare the cognitive performance of patients with PPMS and RRMS with healthy control (HC) subjects. We used a relevant methodology of considering the different clinical characteristics of the patients with these 2 forms of MS by recruiting a large sample of HC subjects that were tightly matched for age, sex, and education level to each group of patients with MS. We hypothesized that patients with PPMS would have more extensive cognitive dysfunction than patients with RRMS. 6 ; an elapsed time since the first MS symptoms of fewer than 10 years for patients with RRMS and 14 or fewer years for patients with PPMS; 18 years of age or older; and French speaker. The exclusion criteria were as follows: other neurologic diseases that could explain the symptoms; SPMS; a history of psychiatric illness with the exception of stable depressive symptoms; starting or stopping antidepressants in the previous 2 months; alcohol, drug, or substance abuse in the previous 2 years; steroid treatment within the last 30 days; and recent cognitive assessment (within less than 1 year). Each PwMS underwent a full neurologic examination. Disability was measured using a French-adapted version 7 of the Expanded Disability Status Scale (EDSS). 8 Healthy controls. HCs were recruited and divided into 20 groups according to age (18-34, 35-44, 45-54, 55-64 , and older than 65 years), sex, and education level (secondary education [usually 12 years of schooling] and graduated [at least baccalaureate]) (table e-1 on the Neurology ® Web site at www.neurology.org). Individuals at least 18 years old who were French speakers were eligible to participate in this study. The exclusion criteria were as follows: a personal history of neurologic disease or psychiatric illness with the exception of stable depressive symptoms; serious head injury; a familial history of MS; starting or stopping antidepressants in the previous 2 months; alcohol, drug, or substance abuse in the previous 2 years; and recent cognitive assessment (within less than 1 year). HCs received compensation for participating in the study.
Standards protocol approvals, registration, and patient consents. The study was approved by the ethics committee, including the institutional review board for human subject research of Bordeaux (CPP Bordeaux 2009/31). All subjects gave written informed consent to participate in the study before their inclusion.
Neuropsychological assessment. PwMS and HCs were assessed with a comprehensive neuropsychological (NP) battery that included some tests from the Brief Repeatable Battery-Neuropsychological, [9] [10] [11] the Paced-Auditory Serial Addition Test-3 seconds (PASAT 3s; testing working memory), the Selective Reminding Test (the SRT and its 3 subscores: SRT-LTS 5 long-term storage, SRT-CLTR 5 consistent long-term retrieval, and SRT-DR 5 delayed recall, which test episodic verbal memory), the 10/36 Spatial Recall Test (SPART) for short-term visuospatial memory, the delayed recall (SPART-DR) of visuospatial memory test, and the Word List Generation test (assessed verbal fluency). A computerized digit-symbol substitution task, called the Computerized Speed Cognitive Test (CSCT), 12 was used instead of the Symbol Digit Modalities Test (SDMT) to assess information processing speed (IPS). In this test, the answer is given orally, and the task lasts 90 seconds. In contrast to the keys for the classical digit/symbol substitution tests such as the SDMT and the digit/symbol subtest of the Wechsler Adult Intelligence Scale, 13 the key is generated automatically by the software for each test session, and it differs with each presentation to prevent learning of the key. The score is the number of accurate answers given in 90 seconds. Computerized tests from the Test of Attentional Performance (TAP) of Zimmermann et al. 14 consisted of the subtests for alertness, visual scanning, flexibility, and visual and auditory divided attention. For alertness, flexibility, and visual scanning, reaction times (RTs) in milliseconds were used to evaluate IPS. For divided attention, the RTs and Accurate Answers (AA) ratios of the simple task (auditory or visual divided attention) to the double task (auditory and visual divided attention) were used to assess attention. The Stroop 45 seconds test, 15 the numerical span test (forward and backward), 16 and the Rey Complex Figure task 17 were also performed. Seven cognitive domains were categorized: IPS, attention, working memory, verbal and visual episodic memory, visuoconstruction, and executive function ( 19 ), and subjective fatigue (UK Neurological Disability Scale fatigue score 20 ) . Subjects were considered to be free of depressive symptoms if their BDI II scores were less than 14, to have mild depressive symptoms if their BDI II scores were between 14 and 19, to have moderate depressive symptoms if their scores were between 20 and 28, and to have severe depressive symptoms if their scores were 29 or more. Based on the UK Neurological Disability Scale fatigue score, subjects were considered to have permanent subjective fatigue affecting daily activities if their score was at least 3.
Statistical analyses. Statistical analyses were performed with
StatView version 5.0 software for Windows. For age, disease duration, and NP scores, the results are shown as the means 6 SDs. For the EDSS, BDI II, anxiety, and fatigue scores, the results are shown as the medians (ranges).
Unpaired t tests were used to compare clinical characteristics, such as sex, age, education level, and disease duration, between patients with PPMS and RRMS. Mann-Whitney U tests were used to compare the median EDSS, BDI II, anxiety, and fatigue scores of the 2 groups of patients with MS.
Each MS patient score was compared with the mean value of that patient's group of HCs matched for age, sex, and education level. The z scores were calculated for each NP score with the following formula: (patient's score 2 mean value of HC group matched for age, sex, and education level)/SD of the matched HC.
For a given NP score, patients were considered impaired if their z scores were below the fifth percentile for their matched HC group. The z scores were also calculated for each cognitive domain using the following formula: sum of the patient's NP z scores for each domain/the number of z scores in each domain. Patients were considered impaired in a given domain if their z scores were below the fifth percentile for their matched HC group. A x 2 test was used to compare the proportions of patients with PPMS and RRMS that were considered impaired in NP and the cognitive domain z scores of these groups of patients. A t test was used to compare the mean of the z scores for the NP tests and for the cognitive domains between patients with PPMS and RRMS. Cohen d was calculated as a measure of effect sizes. This value indicates the magnitude of the mean difference in SD units. According to Cohen, 21 effect sizes can be interpreted as being small (d 5 0.2), medium (d 5 0.5), or large (d $0.8).
Because PwMS had higher scores for depressive symptoms, anxiety, and subjective fatigue than their matched HCs, Pearson correlation analyses were performed between each NP score and the BDI II, STAI-S, and subjective fatigue scores in a post hoc procedure. An analysis of covariance was performed for each NP and cognitive domain z score that differed between patients with PPMS and RRMS. EDSS scores were entered into this post hoc procedure to investigate possible differences in task performance caused by this variable. For all analyses, differences were considered significant when the p values were less than 5%. Patients were not excluded from the statistical analysis if they did not perform all NP tests.
RESULTS Clinical characteristics of patients with PPMS
and RRMS and HCs. Forty-one patients with PPMS, 60 patients with RRMS, and 415 HCs were included in this study. Table 1 shows the clinical characteristics of the PwMS. Based on their demographic and clinical characteristics, 41 patients with PPMS and 60 patients with RRMS were compared with 263 and 310 HCs, respectively. Thirty-six patients with PPMS (87.8%) and 53 patients with RRMS (88.3%) were taking disease-modifying drugs at the time of the examination.
Patients with PPMS and RRMS had higher BDI II (table 2) and STAI-S scores than their respective matched HCs (p , 0.001). There was no significant difference between patients with PPMS and RRMS for the median scores of depressive symptoms and anxiety (table 1) .
Patients with PPMS and RRMS had higher subjective fatigue scores than their respective matched HCs (p , 0.001). There was no difference between the percentages of patients with PPMS and RRMS with subjective fatigue, but patients with PPMS had worse subjective fatigue z scores than the patients with RRMS (p , 0.05).
PwMS performed worse than their matched controls, and patients with PPMS had more extensive cognitive impairment compared with HCs than did patients with RRMS. NP scores were compared between each group of PwMS and the HCs matched for age, sex, and education level. PwMS showed a range of cognitive deficits compared with their matched HCs (figure 1).Three patients with PPMS and 1 patient with RRMS did not perform the visual scanning and flexibility TAP tests because of hand disabilities.
Patients with PPMS performed more poorly than HCs on 16 of 23 NP scores (69.6%), whereas patients with RRMS exhibited lower NP performance on 5 of 23 scores (21.7%) compared with their matched HCs (table 3) . Patients with PPMS performed more poorly than their matched HCs, except for the following scores: RT and AA ratios for auditory divided attention, AA ratio for visual divided attention, AA for visual scanning with a target, 10/36 SPART-Immediate Recall, 10/36 SPART-DR, and the copy for the Rey Complex Figure (table 3 ). Patients with RRMS had lower performances than their matched HCs on the CSCT, the alertness test, the RT for visual scanning with and without a target, and the PASAT 3s (table 3) . Patients with PPMS were more impaired than patients with RRMS according to the following scores: CSCT, Word List Generation 90, AA for flexibility, SRT-CLTR, SRT-DR, and 10/36 SPART-DR (figure 1).
Patients with PPMS were impaired in more cognitive domains than patients with RRMS. Patients with PPMS performed worse than their matched HCs in almost all cognitive domains, except visual episodic memory and visuoconstruction. Patients with RRMS performed worse than their matched HCs in the IPS, For the 2 cognitive domains of executive function and verbal episodic memory, the percentage of PwMS impaired relative to HCs was significantly greater for patients with PPMS than for those with RRMS ( figure 2 ). Unlike patients with PPMS, patients with RRMS were impaired in RT for visual divided attention compared with their matched HCs, but the level of impairment reflected by this score was not different between the patients with PPMS and RRMS (figure 1).
Patients with PPMS performed worse than patients with RRMS in cognitive testing. Regarding cognitive domains, more than 20% of patients with PPMS performed worse than their matched HCs with respect to IPS and verbal episodic memory, whereas more than 20% of patients with RRMS exhibited only IPS impairment when compared with their matched HCs (figure 2).
Patients with PPMS and RRMS differed for the following z scores of NP tests: CSCT (t 5 22.64, p , 0.01), SRT-CLTR (t 5 22.21, p , 0.05), numeral forward span (t 5 22.29, p , 0.05), RT of flexibility (t 5 22.28, p , 0.05), and AA of flexibility TAP tests (t 5 23.17, p , 0.01). Patients with PPMS had lower cognitive z scores than patients with RRMS on these NP tests.
Confounding factors. EDSS and age. Analysis of covariance performed for each NP and cognitive domain z score that differed between patients with PPMS and RRMS showed that after controlling for EDSS and age, the results remained unchanged (see tables e-3 and e-4).
Depressive symptoms, anxiety, and fatigue. Because PwMS had higher scores for depressive symptoms, anxiety, and subjective fatigue than their matched HCs, correlation analyses between NP scores and the BDI II, STAI-S, and subjective fatigue scores were performed. No correlations were found between these variables. DISCUSSION This study allowed the comparison of the cognitive performances of patients with PPMS and patients with RRMS using a relevant methodology by comparing the performances in the same conditions of NP assessment of each group of patients with MS with a large sample of adequate HCs strictly matched for age, sex, and education level. Patients with PPMS had a wide range of cognitive deficits affecting IPS, attention, working memory, executive function, and verbal episodic memory, whereas the impairment in patients with RRMS was limited to IPS, attention, and working memory when compared with their respective matched HCs.
All of the demographic and clinical characteristics of the 2 PwMS groups were similar except for age, sex, and EDSS score. We used z scores based on the data from a large sample of HCs matched for age and sex to account for these differences. To our knowledge, this is the first published study with an HC sample of this size that accounts for age, sex, and education level to adequately characterize the cognitive patterns of patients with PPMS and RRMS. Although, as expected, EDSS scores were higher in patients with PPMS than in those with RRMS, the differences in NP task performance remained unchanged after controlling for EDSS score. This finding is in contrast to the results obtained for 55 patients with PPMS and 108 patients with RRMS in another study. 4 After controlling for EDSS score, patients with RRMS and PPMS were no longer different regarding the PASAT 3s and SDMT scores in that study. Additionally, the observed differences in NP task performance between the 2 MS phenotypes could not be attributable to disease duration because there was no significant difference in disease duration between the PPMS and RRMS patient groups in our study.
Patients with PPMS performed significantly worse than their matched HCs on almost all NP tests. In accordance with previous studies, the cognitive impairment of patients with PPMS included a wide range of domains such as IPS, attention, working memory, verbal episodic memory, and executive function. 2, 4, [22] [23] [24] [25] [26] Although cognitive impairment in PPMS has previously been documented, it is noteworthy that the reported rates vary widely in previous studies (from 7% to 58%). 2, 23, 26 In our study, 47.4% of patients with PPMS were impaired in at least 2 cognitive domains, which is similar to the results of one study comparing patients with PPMS with HCs. 23 Patients with RRMS performed worse than their matched HCs on NP tests for IPS and working memory. It is well known that patients with RRMS frequently show impairment on the SDMT and the PASAT. 27 IPS impairment seems to be a central cognitive defect that is mainly reported in patients with RRMS. [28] [29] [30] The main finding of our study is the difference in frequency and severity of cognitive impairment between PPMS and RRMS patient groups. Patients with PPMS were more frequently impaired in executive function and verbal episodic memory and performed more poorly on working memory and verbal episodic memory tests than patients with RRMS. IPS was frequently impaired in PwMS, but the difference in frequency and severity of IPS impairment between PPMS and RRMS was not significant. The poor IPS performance of patients with PPMS has been reported in previous studies. 4, 30, 31 After controlling for age, sex, Table 3 Mean neuropsychological scores and effect sizes for patients with MS compared with their matched controls a PPMS HCs 31 Patients with PPMS differed from patients with RRMS in verbal episodic memory, unlike previous results. 4 It has been reported that patients with PPMS had greater difficulty acquiring new verbal information than patients with RRMS. 3 Similar to another study, we found no differences in visuospatial memory impairment between patients with RRMS and PPMS as measured by overall 10/36 SPART performance. 4 However, in contrast to that study, patients with PPMS were more frequently impaired than patients with RRMS on the 10/36 SPART-DR tasks in our study. 4 Interestingly, the severity of cognitive impairment was more pronounced in patients with PPMS than in patients with RRMS, because the effect sizes for almost all NP scores were 2-fold higher in the PPMS group than in the RRMS group, which is in accordance with other results (e.g., their SDMT and PASAT 3s results). 4 Our study highlights the usefulness of cognitive testing in patients with PPMS.
One limitation of this study is the absence of brain MRI of the PwMS to better understand the mechanisms underlying the cognitive impairments of patients with these different types of MS. We have previously shown that cognitive impairment may be a marker of diffuse brain abnormalities in early RRMS. 32 The observed group differences in the present study could reflect the fact that patients with PPMS have more widespread brain damage; specifically, pathologic studies suggest that patients with PPMS have diffuse pathology in normal-appearing white matter and gray matter injury (both cortical and deep gray matter damage). 33 
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Figure 2
Percentages of patients with multiple sclerosis (MS) who were impaired compared with their matched controls for each cognitive domain IPS 5 information processing speed; PPMS 5 primary progressive multiple sclerosis; RRMS 5 relapsing-remitting multiple sclerosis. * p , 0.05 for a x 2 test comparing proportions of patients with impairment in the PPMS and RRMS groups.
